AVROBIO Inc. (NASDAQ: AVRO) stock jumped 3.55% on Wednesday to $0.86 against a previous-day closing price of $0.83. With 0.34 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.29 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.8725 whereas the lowest price it dropped to was $0.8302. The 52-week range on AVRO shows that it touched its highest point at $5.07 and its lowest point at $0.56 during that stretch. It currently has a 1-year price target of $3.88. Beta for the stock currently stands at 1.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVRO was up-trending over the past week, with a rise of 14.69%, but this was up by 26.78% over a month. Three-month performance dropped to -15.73% while six-month performance fell -3.40%. The stock lost -80.37% in the past year, while it has lost -77.67% so far this year. A look at the trailing 12-month EPS for AVRO yields -2.50 with Next year EPS estimates of -1.85. For the next quarter, that number is -0.49. This implies an EPS growth rate of 15.90% for this year and 18.50% for next year.
Float and Shares Shorts:
At present, 43.77 million AVRO shares are outstanding with a float of 42.60 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.29 million, which was 0.65% higher than short shares on Sep 14, 2022. In addition to Mr. Geoff MacKay BSc as the firm’s Co- Founder, Pres, CEO & Director, Mr. Erik John Ostrowski M.B.A. serves as its CFO & Treasurer.
Through their ownership of 62.00% of AVRO’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.24% of AVRO, in contrast to 34.24% held by mutual funds. Shares owned by individuals account for 30.91%. As the largest shareholder in AVRO with 8.00% of the stake, GMT Capital Corp. holds 3,494,490 shares worth 3,494,490. A second-largest stockholder of AVRO, K2 & Associates Investment Manage, holds 2,738,410 shares, controlling over 6.27% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in AVRO, holding 1,392,032 shares or 3.19% stake. With a 1.96% stake in AVRO, the JPMorgan Funds – Thematics – Gene is the largest stakeholder. A total of 856,297 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 1.44% of AVRO stock, is the second-largest Mutual Fund holder. It holds 630,579 shares valued at 0.43 million. Vanguard Extended Market Index Fu holds 1.18% of the stake in AVRO, owning 513,661 shares worth 0.35 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVRO since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AVRO analysts setting a high price target of $6.00 and a low target of $2.00, the average target price over the next 12 months is $4.14. Based on these targets, AVRO could surge 597.67% to reach the target high and rise by 132.56% to reach the target low. Reaching the average price target will result in a growth of 381.4% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AVRO will report FY 2022 earnings on 03/16/2023. Analysts have provided yearly estimates in a range of -$1.43 being high and -$2.64 being low. For AVRO, this leads to a yearly average estimate of -$2.27. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. AVROBIO Inc. surprised analysts by $0.03 when it reported -$0.52 EPS against a consensus estimate of -$0.55. The surprise factor in the prior quarter was -$0.07. Based on analyst estimates, the high estimate for the next quarter is -$0.14 and the low estimate is -$0.76. The average estimate for the next quarter is thus -$0.49.
Summary of Insider Activity:
Insiders traded AVRO stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.